OPKO Health (OPK) presents a deeply negative liquidation posture as of March 31, 2026. The MFFAIS cash liquidation value of $143M and liquid liquidation value of $222M against book equity of $1.20B confirm the standard intangible-heavy pharma result: haircut assets recover far less than face-value liabilities. Applying lens haircuts: cash and restricted cash ($356M) recovers at ~100% = $356M; net AR ($80M gross less allowance, ~$80M net) at 90% = $72M; inventory ($64M) at 60% = $39M; PP&E ($73M net) at 60% = $44M; intangibles (finite-lived $496M net + indefinite IPR&D $691M) at 0% = $0; goodwill ($482M) at 0% = $0. Other tangible current/noncurrent assets (prepaid, restricted cash, other) contribute roughly $60M at conservative haircuts. Gross tangible recovery approximates $571M. Against this, liabilities stand at face value: total liabilities $652M, comprising current liabilities $148M, noncurrent liabilities $504M including the 2044 Royalty Financing Notes ($247M senior secured, backed by Pfizer profit-share), convertible notes ($87M), deferred tax liability ($115M which would largely unwind but is kept at face per the lens), and operating/finance lease obligations ($51M combined PV). The result is negative recovery to equity, with the shortfall primarily driven by $1.17B of goodwill and intangibles that carry zero liquidation value. Material developments since the prior filing (FY2025 10-K): (1) The April 1, 2025 Note Exchange retired $159M principal of 2029 Convertible 144A Notes in exchange for 121M shares plus $63.5M cash, materially reducing the debt stack; as of Q1 2026 only $87M in convertible notes remain. (2) The Labcorp Oncology Transaction closed September 2025 for $173M cash plus $19.5M in escrow (scheduled release September 2026); up to $32.5M in contingent consideration remains uncollected. (3) Cash and restricted cash totaled $356M at period end versus operating cash burn of $19M/quarter, providing adequate near-term runway. (4) The 2044 Royalty Financing Notes ($247M, SOFR+7.5% with 4% floor, maturing 2044, interest-only for first four years) represent the dominant long-term debt claim and are secured by Pfizer profit-share payments — collateral that has no standalone liquidation value on the asset side. (5) Accumulated deficit stands at -$2.35B, reflecting chronic operating losses. The filing discusses BARDA contract scope reduction and contingent milestone receivables from Merck, Pfizer, and others in MD&A but these are not separately tagged in XBRL and carry no liquidation value.
▼ Community Notes